Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ICMT | O60725 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27847751 | 1.00 | ADAM17 (0.51) | ADAM17CDC25ACNR2CNR1CTSK | |
| SCHEMBL4934992 | 0.97 | CDC25A (0.54) | ADAM17CDC25ACNR2CNR1CTSK | |
| SCHEMBL4935345 | 0.97 | CDC25A (0.54) | ADAM17CDC25ACNR2CNR1CTSK | |
| SCHEMBL4934999 | 0.97 | CDC25A (0.54) | ADAM17CDC25ACNR2CNR1CTSK | |
| SCHEMBL2839750 | 0.94 | CTSK (0.48) | ADAM17CDC25ACTSKCTSSACE | |
| SCHEMBL2839747 | 0.94 | CTSK (0.48) | ADAM17CDC25ACTSKCTSSACE | |
| SCHEMBL27847752 | 0.91 | CNR1 (0.47) | ADAM17CDC25ACNR2CNR1CTSK | |
| SCHEMBL1711354 | 0.91 | CNR1 (0.47) | ADAM17CDC25ACNR2CNR1CTSK | |
| SCHEMBL2845331 | 0.90 | CTSS (0.48) | ADAM17CNR2CNR1CTSKCTSS | |
| SCHEMBL2845334 | 0.90 | CTSS (0.48) | ADAM17CNR2CNR1CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150510-B2 | Amino acid derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2345635-A1 | AMINO ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172442-A1 | AMINO ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172442-A1 | AMINO ACID DERIVATIVE | OPRL1, OPRK1, SLC1A1 | ADAM17 3078/4885CDC25A 4034/4885CNR2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.